Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 12, 2016, Pages 2108-2121

  Stranahan, Alexis M ^a   Hao, Shuai ^a   Dey, Aditi ^a   Yu, Xiaolin ^a   Baban, Babak ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Diabetes; hippocampus; inflammation; learning and memory; microglia; obesity

Indexed keywords

ENZASTAURIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN RECEPTOR; TUMOR NECROSIS FACTOR; LEPTIN RECEPTOR, MOUSE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ELECTROPHYSIOLOGY; CELL INFILTRATION; CELL ISOLATION; COGNITIVE DEFECT; DIABETES MELLITUS; FLOW CYTOMETRY; FOREBRAIN; HIPPOCAMPAL SLICE; INFLAMMATION; MACROPHAGE MIGRATION; MALE; MICROGLIA; MONONUCLEAR CELL; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OBESITY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN MICROARRAY; ANIMAL; CAPILLARY PERMEABILITY; CELL MOTION; COGNITIVE DYSFUNCTION; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; MACROPHAGE; MEMORY DISORDERS; METABOLISM; MONOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL MOVEMENT; COGNITIVE DYSFUNCTION; INTERLEUKIN-1BETA; MACROPHAGES; MEMORY DISORDERS; MICE; MONOCYTES; OBESITY; RECEPTORS, LEPTIN;

EID: 85001944856     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16642233     Document Type: Article

References (53)

1. Kanneganti TD, and Dixit VD. Immunological complications of obesity. Nat Immunol 2012; 13: 707-712.
2. Kälin S, Heppner FL, Bechmann I, et al. Hypothalamic innate immune reaction in obesity. Nat Rev Endocrinol 2015; 11: 339-351.
3. Stranahan AM. Models and mechanisms for hippocampal dysfunction in obesity and diabetes. Neuroscience 2015; 309: 125-139.
4. Erion JR, Wosiski-Kuhn M, Dey A, et al. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci 2014; 34: 2618-2631.
5. Hao S, Dey A, Yu X, et al. Dietary obesity reversibly induces synaptic stripping by microglia and impairs hippocampal plasticity. Brain Behav Immun 2016; 51: 230-239.
6. Sobesky JL, Barrientos RM, De May HS, et al. High-fat diet consumption disrupts memory and primes elevations in hippocampal IL-1b, an effect that can be prevented with dietary reversal or IL-1 receptor antagonism. Brain Behav Immun 2014; 42: 22-32.
7. Burke SN, and Barnes CA. Senescent synapses and hippocampal circuit dynamics. Trends Neurosci 2010; 33: 153-161.
8. Fotuhi M, Do D, and Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 2012; 8: 189-202.
9. Elias MF, Elias PK, Sullivan LM, et al. Obesity, diabetes and cognitive deficit: the Framingham heart study. Neurobiol Aging 2005; 26: 11-16.
10. Xu WL, Atti AR, Gatz M, et al. Midlife overweight and obesity increase late-life dementia risk: a populationbased twin study. Neurology 2011; 76: 1568-1574.
11. Ho AJ, Raji CA, Becker JT, et al. Obesity is linked with lower brain volume in 700 AD, and MCI patients. Neurobiol Aging 2010; 31: 1326-1339.
12. Whitmer RA, Gustafson DR, Barrett-Connor E, et al. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71: 1057-1064.
13. Convit A, Wolf OT, Tarshish C, et al. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 2003; 100: 2019-2022.
14. Xu W, Caracciolo B, Wang HX, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010; 59: 2928-2935.
15. Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39: 1392-1397.
16. Zhao Z, Nelson AR, Betsholtz C, et al. Establishment and dysfunction of the blood-brain barrier. Cell 2015; 163: 1064-1078.
17. Abbott NJ, Rönnbäck L, and Hansson E. Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
18. Wolburg H, and Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol 2002; 38: 323-337.
19. Gustafson D, Karlsson C, Skoog I, et al. Mid-life adiposity factors relate to blood-brain barrier integrity in late life. J Intern Med 2007; 262: 643-650.
20. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296-302.
21. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-208.
22. Saunders NR, Ek CJ, Habgood MD, et al. Barriers in the brain: a renaissance?. Trends Neurosci 2008; 31: 279-286.
23. Quan N. Immune-To-brain signaling: how important are the blood-brain barrier-independent pathways?. Mol Neurobiol 2008; 37: 142-152.
24. Hanisch UK, and Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-1394.
25. Prinz M, and Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 2014; 15: 300-312.
26. Lanz TV, Becker S, Osswald M, et al. Protein kinase Cb as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013; 110: 14735-14740.
27. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
28. Kanoski SE, Zhang Y, Zheng W, et al. The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J Alzheimers Dis 2010; 21: 207-219.
29. Dey A, Hao S, Erion JR, et al. Glucocorticoid sensitization of microglia in a genetic mouse model of obesity and diabetes. J Neuroimmunol 2014; 269: 20-27.
30. Wosiski-Kuhn M, Erion JR, Gomez-Sanchez EP, et al. Glucocorticoid receptor activation impairs hippocampal plasticity by suppressing BDNF expression in obese mice. Psychoneuroendocrinology 2014; 42: 165-177.
31. Wosiski-Kuhn M, and Stranahan AM. Transient increases in dendritic spine density contribute to dentate gyrus long-Term potentiation. Synapse 2012; 66: 661-664.
32. Meng XW, Heldebrant MP, Flatten KS, et al. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem 2010; 285: 888-902.
33. Asztely F, Kokaia M, Olofsdotter K, et al. Afferentspecific modulation of short-Term synaptic plasticity by neurotrophins in dentate gyrus. Eur J Neurosci 2000; 12: 662-669.
34. Zhang X, Goncalves R, and Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008, Chap. 14: 83: 14.1.1-14.1.14 DOI: 10.1002/0471142735.im1401s83.
35. Distler JH, Jüngel A, Huber LC, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005; 102: 2892-2897.
36. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003; 14: 2503-2515.
37. Ai D, Jiang H, Westerterp M, et al. Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circ Res 2014; 114: 1576-1584.
38. Ronda N, Greco D, Adorni MP, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015; 67: 1155-1164.
39. Hummel KP, Dickie MM, and Coleman DL. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127-1128.
40. Mima A, Ohshiro Y, Kitada M, et al. Glomerularspecific protein kinase C-b-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int 2011; 79: 883-896.
41. Li XL, Aou S, Oomura Y, et al. Impairment of longterm potentiation and spatial memory in leptin receptordeficient rodents. Neuroscience 2002; 113: 607-615.
42. Weeber EJ, Atkins CM, Selcher JC, et al A role for the beta isoform of protein kinase C in fear conditioning. J Neurosci 2000; 20: 5906-5914.
43. Wohleb ES, Powell ND, Godbout JP, et al. Stressinduced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J Neurosci 2013; 33: 13820-13833.
44. Ting JP, and Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109: S21-S33.
45. Murakami T, Frey T, Lin C, et al. Protein kinase cb phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 2012; 61: 1573-1583.
46. Joy SV, Scates AC, Bearelly S, et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005; 39: 1693-1699.
47. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c b inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1, 392 eyes) with diabetic retinopathy in the Protein Kinase C b Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C b Inhibitor-Diabetic Retinopathy Study 2. Retina 2011; 31: 2084-2094.
48. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003; 52: 829-837.
49. Ip BC, Hogan AE, and Nikolajczyk BS. Lymphocyte roles in metabolic dysfunction: of men and mice. Trends Endocrinol Metab 2015; 26: 91-100.
50. Pedersen EB, McNulty JA, Castro AJ, et al. Enriched immune-environment of blood-brain barrier deficient areas of normal adult rats. J Neuroimmunol 1997; 76: 117-131.
51. Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 2010; 298: E395-402.
52. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 2003; 13: 1857-1859.
53. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677.